{"title":"Minimally Invasive Glaucoma Surgery.","authors":"Bogomil Voykov, Verena Prokosch, Jan Lübke","doi":"10.3238/arztebl.m2024.0240","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Approximately 1.4 % of the German population aged 35 to 74 suffers from glaucoma, which is one of the more common causes of blindness. The only evidence-based treatment option at present is lowering the intraocular pressure. Modern minimally invasive surgical procedures hold out the prospect of lowering the intraocular pressure without the risk of serious complications.</p><p><strong>Methods: </strong>This is a selective review of pertinent publications retrieved by a search in PubMed, including randomized, controlled trials and meta-analyses.</p><p><strong>Results: </strong>The intraocular pressure can be lowered with eyedrops, laser procedures, and surgery. Trabeculectomy is the reference standard in glaucoma surgery but leads to complications in 3-15% of cases. In minimally invasive glaucoma surgery, very small stents can be implanted to lower the intraocular pressure. These proce - dures have a better safety profile but are only indicated for mild or moderate glaucoma. The Kahook Dual Blade, iStent inject, and Hydrus Microshunt procedures have been studied in randomized, controlled trials. An additional pressure-lowering effect beyond that of cataract surgery was demonstrated only for the latter two procedures (1.9 mmHg and 1.8 mmHg, respectively). Other procedures have only been investigated in cohort studies to date; a pressure-lowering effect was found for some of them. Moreover, iStent and Hydrus Microshunt have been found to slow the progression of visual field defects.</p><p><strong>Conclusion: </strong>There are robust data documenting the effect of iStent and Hydrus Microshunt in lowering the intraocular pressure and lessening the need for eyedrops. High-quality controlled trials are still needed to test the efficacy of other procedures.</p>","PeriodicalId":11258,"journal":{"name":"Deutsches Arzteblatt international","volume":" Forthcoming","pages":"23-30"},"PeriodicalIF":6.5000,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Deutsches Arzteblatt international","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3238/arztebl.m2024.0240","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Approximately 1.4 % of the German population aged 35 to 74 suffers from glaucoma, which is one of the more common causes of blindness. The only evidence-based treatment option at present is lowering the intraocular pressure. Modern minimally invasive surgical procedures hold out the prospect of lowering the intraocular pressure without the risk of serious complications.
Methods: This is a selective review of pertinent publications retrieved by a search in PubMed, including randomized, controlled trials and meta-analyses.
Results: The intraocular pressure can be lowered with eyedrops, laser procedures, and surgery. Trabeculectomy is the reference standard in glaucoma surgery but leads to complications in 3-15% of cases. In minimally invasive glaucoma surgery, very small stents can be implanted to lower the intraocular pressure. These proce - dures have a better safety profile but are only indicated for mild or moderate glaucoma. The Kahook Dual Blade, iStent inject, and Hydrus Microshunt procedures have been studied in randomized, controlled trials. An additional pressure-lowering effect beyond that of cataract surgery was demonstrated only for the latter two procedures (1.9 mmHg and 1.8 mmHg, respectively). Other procedures have only been investigated in cohort studies to date; a pressure-lowering effect was found for some of them. Moreover, iStent and Hydrus Microshunt have been found to slow the progression of visual field defects.
Conclusion: There are robust data documenting the effect of iStent and Hydrus Microshunt in lowering the intraocular pressure and lessening the need for eyedrops. High-quality controlled trials are still needed to test the efficacy of other procedures.
期刊介绍:
Deutsches Ärzteblatt International is a bilingual (German and English) weekly online journal that focuses on clinical medicine and public health. It serves as the official publication for both the German Medical Association and the National Association of Statutory Health Insurance Physicians. The journal is dedicated to publishing independent, peer-reviewed articles that cover a wide range of clinical medicine disciplines. It also features editorials and a dedicated section for scientific discussion, known as correspondence.
The journal aims to provide valuable medical information to its international readership and offers insights into the German medical landscape. Since its launch in January 2008, Deutsches Ärzteblatt International has been recognized and included in several prestigious databases, which helps to ensure its content is accessible and credible to the global medical community. These databases include:
Carelit
CINAHL (Cumulative Index to Nursing and Allied Health Literature)
Compendex
DOAJ (Directory of Open Access Journals)
EMBASE (Excerpta Medica database)
EMNursing
GEOBASE (Geoscience & Environmental Data)
HINARI (Health InterNetwork Access to Research Initiative)
Index Copernicus
Medline (MEDLARS Online)
Medpilot
PsycINFO (Psychological Information Database)
Science Citation Index Expanded
Scopus
By being indexed in these databases, Deutsches Ärzteblatt International's articles are made available to researchers, clinicians, and healthcare professionals worldwide, contributing to the global exchange of medical knowledge and research.